Core Insights - Waystar Holding (WAY) reported revenue of $270.65 million for the quarter ended June 2025, marking a year-over-year increase of 15.4% and an EPS of $0.36 compared to $0.04 a year ago [1] - The reported revenue was slightly below the Zacks Consensus Estimate of $271 million, resulting in a revenue surprise of -0.13%, while the EPS exceeded the consensus estimate of $0.33 by 9.09% [1] Revenue Breakdown - Subscription revenue reached $131.11 million, surpassing the four-analyst average estimate of $126.61 million [4] - Revenue from implementation services and other totaled $1.26 million, which was below the four-analyst average estimate of $1.46 million [4] - Volume-based revenue was reported at $138.29 million, exceeding the average estimate of $130.74 million from four analysts [4] Stock Performance - Over the past month, Waystar's shares have returned -9.4%, contrasting with the Zacks S&P 500 composite's increase of +3.4% [3] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential for outperformance in the near term [3]

Core Insights - AtriCure reported revenue of $136.14 million for the quarter ended June 2025, reflecting a year-over-year increase of 17.1% and surpassing the Zacks Consensus Estimate of $130.15 million by 4.61% [1] - The company achieved an EPS of -$0.02, a significant improvement from -$0.17 in the same quarter last year, resulting in an EPS surprise of 86.67% against the consensus estimate of -$0.15 [1] Revenue Performance - U.S. Revenue in Pain Management reached $21.17 million, exceeding the average estimate of $18.36 million, marking a year-over-year increase of 41.1% [4] - International Revenue in Pain Management was $2.03 million, slightly below the average estimate of $2.24 million, but still showing a year-over-year growth of 63.8% [4] - U.S. Revenue for Total Ablation was $44.31 million, falling short of the average estimate of $62.64 million, representing a decline of 23.1% year-over-year [4] - International Revenue for Total Ablation was $12.72 million, compared to the average estimate of $14.37 million, with a year-over-year increase of 4.5% [4] - Total U.S. Revenue amounted to $110.58 million, surpassing the average estimate of $105.65 million, reflecting a year-over-year growth of 15.8% [4] - International Revenue for Appendage Management was $10.8 million, exceeding the average estimate of $10.33 million, with a year-over-year increase of 26.3% [4] - U.S. Revenue for Open Ablation was $36.47 million, slightly above the average estimate of $35.47 million, showing an 18.6% increase year-over-year [4] - International Revenue for Open Ablation reached $10.35 million, exceeding the average estimate of $10.15 million, with a year-over-year growth of 12.9% [4] - U.S. Revenue for Minimally Invasive Ablation was $7.84 million, below the average estimate of $8.81 million, reflecting a decline of 33.7% year-over-year [4] - International Revenue for Minimally Invasive Ablation was $2.37 million, surpassing the average estimate of $1.98 million, with a year-over-year increase of 34.5% [4] - U.S. Revenue for Appendage Management was $45.11 million, exceeding the average estimate of $43.01 million, representing an 18.9% year-over-year increase [4] - Total International Revenue was $25.56 million, surpassing the average estimate of $24.69 million, with a year-over-year growth of 23.3% [4] Stock Performance - AtriCure's shares have returned +1.4% over the past month, compared to the Zacks S&P 500 composite's +3.6% change, indicating a performance in line with the broader market [3]

Core Insights - Agilysys reported revenue of $76.68 million for the quarter ended June 2025, reflecting a year-over-year increase of 20.7% [1] - The earnings per share (EPS) for the quarter was $0.33, up from $0.30 in the same quarter last year [1] - The reported revenue exceeded the Zacks Consensus Estimate of $74.47 million by 2.96%, while the EPS fell short of the consensus estimate of $0.39 by 15.38% [1] Revenue Breakdown - Product revenue was $9.95 million, slightly below the estimated $10.49 million, representing a year-over-year increase of 0.8% [4] - Subscription and maintenance revenue reached $48.62 million, surpassing the estimated $46.62 million, with a significant year-over-year increase of 27.8% [4] - Professional services revenue amounted to $18.1 million, exceeding the estimated $17.26 million, and showed a year-over-year growth of 16.1% [4] Stock Performance - Agilysys shares have returned 6.2% over the past month, outperforming the Zacks S&P 500 composite's return of 5.4% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Core Insights - Postal Realty Trust (PSTL) reported a revenue of $22.15 million for the quarter ended March 2025, reflecting a year-over-year increase of 28.1% [1] - The earnings per share (EPS) for the quarter was $0.32, a significant improvement from -$0.01 in the same quarter last year [1] - The reported revenue exceeded the Zacks Consensus Estimate of $21.14 million by 4.80%, while the EPS also surpassed the consensus estimate of $0.30 by 6.67% [1] Revenue Breakdown - Rental income was reported at $21.48 million, exceeding the average estimate of $19.58 million by analysts, marking a 29.4% increase compared to the previous year [4] - Fee and other revenues were $0.67 million, slightly below the average estimate of $0.77 million, representing a decrease of 1.9% year-over-year [4] Stock Performance - Over the past month, shares of Postal Realty Trust have returned -7.9%, contrasting with the Zacks S&P 500 composite's -0.2% change [3] - The stock currently holds a Zacks Rank 1 (Strong Buy), suggesting potential for outperformance in the near term [3]

Core Viewpoint - Bausch + Lomb reported a revenue of $1.14 billion for the quarter ended March 2025, reflecting a 3.5% increase year-over-year, but an EPS of -$0.07, contrasting with $0.07 in the same quarter last year, indicating challenges in profitability despite revenue growth [1]. Revenue Performance - Vision Care revenues reached $656 million, slightly above the average estimate of $654.55 million, marking a year-over-year increase of 3.3% [4]. - Surgical revenues amounted to $214 million, exceeding the average estimate of $206.66 million, with a year-over-year growth of 8.6% [4]. - Pharmaceuticals revenues were reported at $267 million, below the average estimate of $284.94 million, showing no change year-over-year [4]. - Total product sales were $1.13 billion, compared to the average estimate of $1.15 billion, reflecting a year-over-year increase of 3.6% [4]. - Other revenues were reported at $4 million, below the average estimate of $5 million, indicating a significant year-over-year decline of 20% [4]. Stock Performance - Bausch + Lomb shares have returned -2.7% over the past month, in contrast to the Zacks S&P 500 composite's -0.2% change, suggesting underperformance relative to the broader market [3]. - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3].

Core Insights - PPG Industries reported a revenue of $3.68 billion for the quarter ended March 2025, reflecting a 14.5% decline year-over-year, while EPS decreased to $1.72 from $1.86 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate by 0.77%, and the EPS surpassed the consensus estimate by 6.17% [1] Financial Performance - Net Sales in Performance Coatings reached $1.27 billion, exceeding the average estimate of $1.20 billion, but showing a significant year-over-year decline of 51.6% [4] - Net Sales in Architectural Coatings were reported at $857 million, below the average estimate of $918.35 million [4] - Net Sales in Industrial Coatings amounted to $1.56 billion, slightly above the average estimate of $1.53 billion, with an 8% year-over-year decline [4] Segment Income - Segment Income for Performance Coatings was $274 million, slightly above the average estimate of $273.54 million [4] - Segment Income for Architectural Coatings was $118 million, below the average estimate of $142.24 million [4] - Segment Income for Industrial Coatings reached $215 million, exceeding the average estimate of $173.71 million [4] Stock Performance - PPG Industries' shares have returned -5.8% over the past month, compared to a -0.8% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Insights - German American Bancorp (GABC) reported a revenue of $81.41 million for Q1 2025, marking a year-over-year increase of 33.9% and exceeding the Zacks Consensus Estimate of $79.1 million by 2.92% [1] - The company's EPS for the same quarter was $0.79, up from $0.64 a year ago, representing a surprise of 9.72% compared to the consensus estimate of $0.72 [1] Financial Performance Metrics - Efficiency ratio was reported at 61.3%, higher than the estimated 56.3% by analysts [4] - Net Interest Margin stood at 4%, surpassing the average estimate of 3.7% [4] - Net charge-offs to average loans were 0%, compared to the estimated 0.1% [4] - Total Average Interest Earning Assets reached $6.92 billion, exceeding the estimate of $6.85 billion [4] - Net Gains on Sales of Loan were $0.83 million, slightly below the estimated $0.90 million [4] - Total Non-interest Income was reported at $14.84 million, lower than the estimated $15.95 million [4] - Net interest income (FTE) was $67.89 million, compared to the average estimate of $62.41 million [4] - Service charges on deposit accounts were $3.49 million, below the estimated $3.81 million [4] - Net Interest Income was reported at $66.57 million, exceeding the estimate of $63.51 million [4] Stock Performance - Shares of German American Bancorp have returned -3.1% over the past month, outperforming the Zacks S&P 500 composite's -4.3% change [3] - The stock currently holds a Zacks Rank 1 (Strong Buy), indicating potential for outperformance in the near term [3]